C CELLPOINT
LIVE

Serial Number

97787004

Owner

Galapagos NV

Attorney

Alexandra MacKay

Filing Date

Feb 8, 2023

Add to watchlist:

No watchlists yet
View on USPTO

C CELLPOINT Trademark

Serial Number: 97787004 • Registration: 7498517

C CELLPOINT is a trademark filed by Galapagos NV on February 8, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Galapagos NV (19 trademarks)

Mechelen B-2800 , BE

Entity Type: 03

Trademark Details

Filing Date

February 8, 2023

Registration Date

September 10, 2024

Published for Opposition

June 25, 2024

Goods & Services

Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals

Pharmaceutical substances and preparations for human use, namely, pharmaceutical preparations and engineered patient T cells for the treatment of cancer; biopharmaceutical substances and preparations for human use, namely, biopharmaceutical preparations and engineered patient T cells for the treatment of cancer; clinical diagnostic reagents for medical use

Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others being engineered patient T-cells; medical services, namely, Stemcell and celltherapy services; Medical services relating to the removal, treatment and processing of human cells

Medical, scientific and industrial research services in the field of pharmaceuticals, engineered patient T-cells, cell therapy, and gene therapy; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression, namely, analysis and testing of cells to determine the presence of particular genes; analysis and testing of cells to determine efficacy for treatment of cancer; development, examination, namely, quality control, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; development of test systems in the nature of testing procedures and protocols, computer software for testing, reagents and testing kits for testing for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer databanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services; scientific research in the nature of conducting clinical trials for others; Providing information about the results of clinical trials for pharmaceutical products; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 10, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 25, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 25, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 5, 2024 NONP
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Feb 16, 2024 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 9, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 7, 2024 CRFA
ASSIGNED TO LIE
Feb 7, 2024 ALIE
ASSIGNED TO EXAMINER
Nov 6, 2023 DOCK
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 17, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 25, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 25, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 25, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 21, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Mar 1, 2023 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 28, 2023 NWOS
NEW APPLICATION ENTERED
Feb 11, 2023 NWAP